{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T03:32:28Z","timestamp":1781839948473,"version":"3.54.5"},"reference-count":22,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>We explored patient front\u2010line treatment preferences in newly diagnosed stage III\/IV classic Hodgkin lymphoma (cHL). The CONNECT patient survey, administered online from 30 December 2020 to 1 March 2021, examined preferences overall and by age at diagnosis in 182 adult patients diagnosed with stage III\/IV cHL within the past 10\u2009years in the United States. At diagnosis, patients' median age was 36\u2009years; 66% of patients were younger (aged 16\u201341\u2009years) and 34% older (aged 42\u201385\u2009years). When asked about initial treatment goals, 74% of patients ranked cure as their first or second goal (86% younger vs. 52% older patients; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). At diagnosis, 72% of patients preferred aggressive treatment, and 85% were willing to accept more short\u2010term risks in exchange for a better\u2010working therapy long term. For long\u2010term risks, younger versus older patients were significantly more concerned about second cancers (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and fertility issues (<jats:italic>p<\/jats:italic>\u2009=\u20090.007), whereas older patients were more concerned about lung damage (<jats:italic>p<\/jats:italic>\u2009=\u20090.028) and infections (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Most patients (94%) reported having a caregiver at some point, but 99% of these patients retained some control of treatment decisions. Collectively, these survey results highlight patient treatment preferences and differences in treatment goals and long\u2010term side effect concerns based on patient age.<\/jats:p>","DOI":"10.1111\/bjh.19307","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T14:09:14Z","timestamp":1707314954000},"page":"1262-1270","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patient preferences in the treatment of stage <scp>III<\/scp>\/<scp>IV<\/scp> classic Hodgkin lymphoma: Results from the <scp>CONNECT<\/scp> cross\u2010sectional survey"],"prefix":"10.1111","volume":"204","author":[{"given":"Darcy R.","family":"Flora","sequence":"first","affiliation":[{"name":"Research Department Gryt Health  Rochester New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K.","family":"Parsons","sequence":"additional","affiliation":[{"name":"Department of Medicine and Pediatrics Tufts University School of Medicine, Tufts Medical Center  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Liu","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, Pfizer Inc.  Bothell Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina S.","family":"Yu","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, Pfizer Inc.  Bothell Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Holmes","sequence":"additional","affiliation":[{"name":"Oncology Ipsos Healthcare  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Flores","sequence":"additional","affiliation":[{"name":"Genesis Research  Hoboken New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Fanale","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, Pfizer Inc.  Bothell Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Surinach","sequence":"additional","affiliation":[{"name":"Genesis Research  Hoboken New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Byrd","sequence":"additional","affiliation":[{"name":"Research Department Gryt Health  Rochester New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6900-1824","authenticated-orcid":false,"given":"Andrew M.","family":"Evens","sequence":"additional","affiliation":[{"name":"Division of Blood Disorders Rutgers Cancer Institute of New Jersey  New Brunswick New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/920898"},{"key":"e_1_2_10_3_1","unstructured":"National Institutes of Health (NIH) National Cancer Institute.Cancer Stat Facts: Hodgkin Lymphoma [Internet]. 2023 [cited 2023 Oct 12]. Available from:https:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html"},{"key":"e_1_2_10_4_1","unstructured":"National Institutes of Health (NIH) National Cancer Institute.Hodgkin Lymphoma. Recent Trends in SEER Age\u2010Adjusted Incidence Rates 2000\u20132020 [Internet]. 2023 [cited 2023 Oct 12]. Available from:https:\/\/seer.cancer.gov\/statistics\u2010network\/explorer\/application.html?site=83&data_type=1&graph_type=2&compareBy=sex&chk_sex_3=3&chk_sex_2=2&rate_type=2&race=1&age_range=1&stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#graphArea"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn384"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29105"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25856"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199211193272102"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3298"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206125"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3196_LBA5"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4"},{"key":"e_1_2_10_13_1","doi-asserted-by":"crossref","unstructured":"LynchRC AligSK UjjaniCS PohC WarrenEH SmithSD et\u00a0al.4429: Durable remissions in advanced stage and molecularly high risk untreated classic Hodgkin lymphoma with pembrolizumab + AVD. ASH Annual Meeting & Exposition. San Diego CA. 9\u201312 December 2023.","DOI":"10.1182\/blood-2023-179547"},{"key":"e_1_2_10_14_1","doi-asserted-by":"crossref","unstructured":"AdvaniRH AvigdorA BalariAMS LavieD HohausS ZauchaJM et\u00a0al.3068: Efficacy and safety of pembrolizumab and chemotherapy in newly\u2010diagnosed early unfavorable or advanced classic Hodgkin lymphoma: the phase 2 KEYNOTE\u2010C11 study. ASH Annual Meeting & Exposition. San Diego CA. 9\u201312 December 2023.","DOI":"10.1182\/blood-2023-181171"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000971152.58813.12"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15566"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1783443"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon\u20102023\u20100358"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00811"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520\u2010023\u201008120\u20108"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34479"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1192121"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520\u2010021\u201006538\u20106"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T15:37:52Z","timestamp":1712763472000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.19307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1111\/bjh.19307"],"URL":"https:\/\/doi.org\/10.1111\/bjh.19307","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]},"assertion":[{"value":"2023-10-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}